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ABSTRACT 
 
Implantable Microdevice for the Treatment of Hydrocephalus 
 
Jonghyun Oh 
 
Hongseok (Moses) Noh, Ph.D. 
 
We present a novel microdevice for the treatment of hydrocephalus. 
Hydrocephalus is a pathological condition in which excessive 
cerebrospinal fluid (CSF) is accumulated within the subarachnoid space of 
the brain due to deficient arachnoid granulations, resulting in the brain 
damage or death. Current treatment for hydrocephalus is to surgically 
implant a shunt device to drain the excessive fluid from the ventricles to 
peritoneal cavity or other parts of the body. This method has over 50% 
failure rate due to occlusions and mechanical failures of shunt components. 
The proposed microfabricated device can mimic the function of normal 
arachnoid granulations and thus can replace the deficient arachnoid 
granulations. The microfabricated arachnoid granulations (MAG) consist 
of arrays of microvalves and microneedles.  
The microvalves are made of a PDMS/Parylene composite layer 
and have a 3-D dome petal shape.  Such geometry enables the microvalve 
to rectify fluid flow in the forward and backward direction due to pressure 
differentials like normal arachnoid granulation. Microvalve design was 
optimized using 3-D numerical simulation. The microvalves were 
fabricated using three main microfabrication techniques: diffuser 
lithography for dome-shaped SU-8 mold fabrication, thin polymer film 
17 
 
deposition and reflow for PDMS/Parylene membrane formation, and 
excimer laser machining for valve opening. The pressure drop vs. flow 
rate characteristics of the fabricated microvalve was investigated through 
in-vitro flow tests using a bench-top CSF simulator. The results showed 
that a 10x10 microvalve array with combined opening shape is optimal for 
our application.  
The microneedle array is to surgically pierce the dura mater 
membrane after being assembled with the microvalve. The microneedles 
were fabricated using three main techniques: diffraction photolithography 
for tapered SU-8 needle fabrication, RIE etching for needle sharpening, 
and excimer laser machining for through-hole creation. Puncture tests 
were conducted using pig’s dura mater and the microneedles coated with a 
Ti layer showed promising results (16 out of 100 needles pierced dura and 
the needles were not deformed). Blood adhesion tests were also carried out 
using human blood simulating the CSF dynamics and no significant 
platelet adhesion was observed at the microneedles. The MAG presented 
in this dissertation demonstrates a great potential for the treatment of 
hydrocephalus. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background of hydrocephalus 
 
1.1.1 Cerebrospinal fluid (CSF) 
CSF is the acronym of Cerebrospinal fluid which is a clear and 
colorless fluid. This fluid contains small quantities of glucose and protein. 
CSF fills the ventricules of the brain and the central canal of the spinal 
cord. 
Ependyma is an epithelial membrane in the central nervous system 
facing the ventricular system of the brain and spinal cord [1]. It is believed 
that this membrane is involved in the production of CSF at a rate of 
0.3~0.5 ml/min [2]. Figure 1-1 shows the CSF circulation in the brain. 
CSF produced in the Ependyma of the Choroid plexus passes through 
third and fourth ventricles by diffusion and then CSF arrives in the 
subarachnoid space. It circulates around brain and spinal cord. Arachnoid 
granulations periodically permit CSF accumulated in the subarachnoid 
space to be diverted into the superior sagittal sinus. The average volume of 
intracranial CSF is 125 ml in an adult. The CSF pressure in the 
subarachnoid area varies according to the age group. The pressure is 
estimated to be 40~50 mmH2O for infants and 40~100 mmH2O for 
children. In adults, it remains constant at about 150 mmH2O which is 
usually about 40~50 mmH2O above the intracranial 
19 
 
Figure 1-1. CSF circulation in the brain. (Copyright ⓒ 1998, 
Lynne Larson, All rights reserved.). CSF flow: Choroid plexus  
third ventricle  fourth ventricle  subarachnoid space  
arachnoid granulation  sagittal sinus. 
20 
 
over the intracranial venous pressure. The total volume of CSF is turned 
over 4~5 times in a 24h period. The production and absorption of CSF 
maintains in a dynamic equilibrium that keeps the pressure constant [2]. 
CSF in the brain has three major roles. First, CSF surrounds the 
brain and cushions the brain and spinal cord from some shocks. Secondly, 
CSF serves to rinse the metabolic waste from the nervous system. Lastly, 
the constant presence of adequate levels of CSF maintains pressure 
balance in the brain. Failure to fulfill any of these major roles may cause 
serious damage to the nervous system, resulting in brain damage or death. 
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1.1.2 Arachnoid granulations 
As shown in Figure 1-2, arachnoid granulations are small 
protrusions of the arachnoid (membranes convering the brain and spinal 
cord) through the dura mater. CSF is produced inside ventricles and then 
leaves to surround the whole brain and spinal cord. Arachnoid granulation 
enables excessively accumulated CSF to be drained into the superior 
sagittal sinus (blood stream), which keeps the balance of the intracranial 
pressure in the brain. The first exposure of the world to the arachnoid 
granulations was in the 16th and 17th century [3]. Pacchioni, in 1705, 
reported the clustering of arachnoid villi along the sagittal sinus [4]. 
Luschka and Trolard investigated the arachnoid structure penetrating a 
small space of the sagittal sinus in 19th century [5]. Later, Key and Retzius 
confirmed the role of villi as a natural valve [6]. In the twentieth century, a 
differential hydrostatic pressure as a working force of arachnoid 
granulation was reported by Davson [7]. Most research over the last 
century has focused on further characterizing the ultrastructure and 
functional attributes of AG, with less attention to its macroscopic anatomy, 
distribution, and total surface area [8]. 
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(a) 
(b) 
Figure 1-2. Arachnoid meninges [8]: (a) schematic of cross-sectional view 
near AG, (b) coronal section of human brain, (c) appearance of human 
arachnoid granulations. 
Bone Arachnoid 
granulations 
Arachnoid
Dura
Dura 
SSS 
(c) 
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1.1.3 Hydrocephalus 
Hydrocephalus can be defined as an excessive accumulation of 
CSF within the subarachnoid space of the brain. This accumulation causes 
high pressure difference above 200 mmH20 in the brain, which results in 
central nervous system problems.  
Hydrocephalus can be categorized into two types of 
communicating and non-communicating hydrocephalus according to the 
conditions. Non-communicating hydrocephalus occurs when the flow of 
CSF is blocked along the narrow channels between the ventricles. 
Communicating hydrocephalus occurs when the flow of CSF is blocked 
after passing through the ventricles [9]. The most common type is 
communicating hydrocephalus. Figure 1-3 shows a baby whose head 
swelling was caused by severe communicating hydrocephalus. Without 
proper medical care, this pediatric hydrocephalus results in developmental 
disabilities or death. Children and adults may experience the typical 
symptoms such as gait disturbance, balance problems, and headache [10]. 
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Figure 1-3. A baby who is suffering from communicating 
hydrocephalus. This disease causes swelling of the brain. (an image 
from Wikimedia Commons) 
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1.2 Diagnosis, treatment, and problems 
 
1.2.1 Diagnosis of hydrocephalus 
Nowadays, hydrocephalus is characterized and diagnosed by 
clinical symptoms of dementia (a loss of brain function that occurs with 
certain diseases), urinary incontinence, and gait disturbance as well as 
analysis of neuroimaging by ultrasound, computed tomography (CT) and 
magnetic resonance imaging (MRI) coupled with mean value of 
intracranial pressure (ICP) measured by a epidural pressure sensor [11]. 
An ultrasound is a sophisticated method of outlining structures within the 
head using high frequency sound waves. It can be performed to examine 
the size of the ventricles especially for babies. However, once the skull 
bones have closed over the fontanels, this method cannot be done as 
ultrasound cannot go through bone. Normally a CT brain scan is a 
technique in which tiny beams of x-ray outline the skull, brain, ventricules, 
and subarachnoid space. In addition to visualizing the size and shape of 
the ventricules, abnormalities such as tumors, cysts, and other pathology 
can also be seen. A MRI is a non-invasive diagnostic tool that uses radio 
signals and a magnetic to form computer images of the brain, its 
ventricular system and coverings, and pathological lesions.  
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1.2.2 Review of treatment methods 
 
a. Patents  
From the middle of the 20th century onward, a lot of patents for the 
treatment of hydrocephalus have been introduced. Existing patents 
pertaining to hydrocephalus treatment can be focused on the shunt system. 
Shunt system has been the fundamental treatment method for 
hydrocephalus for nearly 50 years. Samuel Schwartz (1963) acquired first 
patent about a ventricular-venous shunt device comprised of a catheter and 
two one-way check valves, which can drain cerebrospinal fluid into the 
circulatory system [12]. His apparatus design was focused on several key 
points: a small diameter to avoid providing space for hostile organisms, a 
simple concept to reduce the valve failure, and a hydraulic design to 
eliminate eddy flows. Figure 1-4 shows graphics of the invented apparatus. 
Figure 1-4(a) is one-way check valve, which is normally open under 
forward flow and normally closed under backward flow by deforming a 
flexible plastic (13 in Figure 1-4(a)).  Richard H. Ames (1969) invented a 
two-way flushing device that consists of two chambers and a catheter with 
a check valve (17 in Figure 1-5) [13]. This device can easily check 
blockage of the shunt by tissue particles by compressing either of the two 
chambers Figure 1-5(a) shows a cross-sectional view of the shunt flushing 
device and (b) shows a schematic of the shunt system inserted in a patient. 
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Figure 1-4. Ventriculo-Venous shunt device invented by Samuel 
Schwartz. (a) One-way checkvalve which is normally open under 
forward flow and closed deforming a flexible plastic (13 in Figure) under 
backward flow and (b) the shunt system inserted in the brain of a patient. 
Flexible plastic 
Flow direction 
(a) 
(b) 
Forward flow 
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Figure 1-5. A two-way flushing device for treatment of hydrocephalus. 
(a) a cross-sectional view of a flushing device which can easily check 
blockage of the shunt by tissue particles carried in the fluid 
compressing either of two chambers and (b) a partly diagrammatic 
view of a shunt system inserted in a patient. 
(b) (a) 
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Figure 1-6. A ball type shunt valve invented by Salmon Hakim and 
Carlos A. Hakim. This valve is normally closed and open when a 
spherical ball is pushed by forward flow. 
Spring 
Ball 
30 
 
Salmon Hakim and Carlos A.Hakim (1983) invented a shunt system with 
ball type check valve, which can vent CSF from a cerebroventricular 
catheter to a drainage catheter [14]. This prevents brain debris or CSF 
proteins clogging a thin slit in the valve. Figure 1-6 shows the invented 
shunt valve, which is opened when a spherical ball is pushed by forward 
flow. Bernard Marion (1987) invented a ball type shunt valve with a 
rotating rotor [15]. This design avoids the siphon effect when the patient 
moves between vertical and horizontal positions, and it can be easily 
calibrated at any desired closing pressure for implantation. Figure 1-7 is a 
schematic of the cross-sectional view of the invented valve. When the 
body is moving, a spring blade (9 in Figure 1-7) fixed to the rotor (10) 
rotates along the cylindrical wall (6). Inlet flow results in a pressure 
differential, which pushes the ball (8) inward, and this pushing force 
deforms the blade simultaneously. This whole valve mechanism controls 
the CSF flow. Additionally, Alain Lecuyer (1994) invented an implantable 
drainage valve for the treatment of hydrocephalus [16]. This valve can 
avoid hyperdrainage under normal pressure differential when the patient 
rises from a lying or recumbent position to a standing position. As shown 
in Figure 1-8, the invented valve is implanted vertically when the patient’s 
head is upright. When the patient is in a recumbent position, the weight 
(24 in Figure 1-8) provides additional compressive force against the spring 
(22) to maintain the valve in a closed condition. Christoph Miethke (2005) 
invented a controllable hydrocephalus valve comprised of an electrical 
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Figure 1-7. A ball type shunt valve with a rotating rotor invented by 
Bernard Marion. This valve can avoid the siphon effect when a patient 
moves between verticle and horizontal positions and be easily calibrated 
at any desired closing pressure for implantation. When the body is 
moving, spring blade (9 in Figure) fixed to the rotor (10) rotates along 
cylindrical wall (6). Inlet flow by pressure differential pushes the ball 
(8) inward. This force exerted on the ball deforms the blade. This 
mechanism controls the CSF flow.  
(Ball) 
Spring blade 
(Rotor) 
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Figure 1-8. A ball type shunt valve with a rotating rotor invented by 
Bernard Marion. 10: valve, 12: valve body, 14: inlet, 16: outlet, 18: 
tapered valve seat, 20 spherical closure member, 22: spring, 24-26-28: 
weights, 32: upstream section, and 34: downstream section. The 
invented valve is implanted vertically when the patient’head is upright. 
When the patient is in a recumbent position, the weight (24 in Figure) 
provides additional compressive force against the spring (22) to 
maintain the valve in a closed condition. 
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Figure 1-9. A schematic of a hydrocephalus valve invented by 
Christoph Miethk. 1: electronic system, 2: coil, 3: slide, 4: sphere, 
5: outlet, 6: blind hole, 7: spring, 8: battery, and 9: detector. An 
electronic system is supplied by a battery. A current of this system 
is applied to a coil which generates a magnetic field in order to 
move the slide. The detector can detect a slide position. This slide 
can move the sphere between rest position 1 and rest position 2 in 
order to open and close the valve. When the sphere is in the rest 
position 2, fluid can go outside. The control of the slide may take 
place from a time control or a control calculated by complex 
algorithm. 
Rest position 1 Rest position 2 
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Figure 1-10. A self adjusting hydrocephalus valve invented by Meir 
Rosenberg. When the blocking member (46 in Figure) is seated against 
the valve seat (44), CSF cannot enter through the valve seat and into 
the chamber.  When the blocking member is pushed toward bellows 
(52), bellows collapses and fluid can pass through the valve.          
 
Blocking member 
CSF  
flow 
Valve seat 
Inlet 
Outlet 
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control system opening and closing the valve [17]. This system can 
improve adaptation to the specific circumstances of the patient. In Figure 
1-9, it is shown that the system is supplied power from a battery. The 
current of this system is applied to a coil, which generates a magnetic field 
that can move the slide, and a detector can track this slide position. This 
slide can move the sphere between rest position 1 and rest position 2 in 
order to open and close the valve. When the sphere is in the rest position 2, 
fluid can flow outwards. The control of the slide may take place through a 
time control or a control calculated by a complex algorithm. Meir 
Rosenberg (2008) invented a self-adjusting hydrocephalus valve, which 
can continue to drain CSF at a rate proportional to the average pressure 
difference across the valve [18]. In the valve mechanism in Figure 1-10, 
when the blocking member (46 in Figure 1-10) is seated against the valve 
seat (44), CSF cannot enter through the valve seat and into the chamber.   
When the blocking member is pushed toward the bellows (52), the bellows 
collapses, and fluid can pass through the valve.          
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b. Journal papers  
Even though the most appropriate treatment for hydrocephalus has 
been shunt surgery, significant problems such as occlusion, infection, and 
malfunction remain. Also, there have been no alternative treatments so far. 
However, the following journal papers present novel attempts at 
hydrocephalus treatment. 
Yoon et al. (2004) reported a novel cerebrospinal fluid shunt 
system for the hydrocephalus patients as shown in Figure 1-11 [19]. The 
CSF shunt system consists of a micro telemetry pressure sensor, an 
electromagnetic micropump and a controller. The pressure sensor has a 
flexible p+ diaphragm and a planar copper coil that construct an LC 
resonant circuit. The cerebrospinal pressure is measured from the phase 
shift at the resonance frequency. The proposed telemetry pressure sensor 
can measure the intracranial pressure ranging from 0 to 120 mm H2O. The 
micropump consists of an actuator diaphragm and a pair of passive valves. 
Each device is fabricated by micromachining technology and tested to 
obtain the characteristic. If the applied pressure is larger than 110mm H2O, 
the fabricated micropump operates and drains. Fig. 18(d) shows the 
measurement system for the in-vitro test of the closed-loop shunt system. 
When the pressure is lower than 90mm H2O by the water drainage, and the 
micropump stops operating. When the pressure is lower than 90mm H2O 
by the water drainage, and the micropump stops operating. The 
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(c) Micro pump 
Micro pump/ check valve 
Monitor/ controller/ battery 
Shunt tube 
Antenna coils for power transmission 
& telemetry pressure sensor 
(a) 
(b)  Flap valve 
(d) 
Figure 1-11. Micro devices for shunt system. (a) schematic view of a CSF shunt 
system, (b)  micro pump part: flap valve, (c) micro pump: actuator, (d) the 
measurement system for the in-vitro test of the closed-loop shunt system. 
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feasibility of the proposed shunt system is evaluated with the in vitro 
performance test. 
N. Al-Zubi et al. (2009) proposed a new approach to automate and 
improve the treatment and management of hydrocephalus through a 
cognitive system over a distributed network of hydrocephalus patients 
with intelligent shunt system [20].  As shown in Figure 1-12, the 
intelligent system specifically addresses the use of the valuable 
information in the ICP signal coupled with patient feedback and surgeon 
examination and enforced by the eShunt agent, to improve understanding 
and management of hydrocephalus. A requirement of a considerable 
amount of ICP analysis and treatment data is necessary to build a self-
learning and robust classification system for ICP waveforms and 
hydrocephalus patients. This approach will tackle challenges in analysing, 
collecting and managing ICP data, by providing a distributed system of 
eShunt agents that manage patients autonomously, and share information 
between them. It can reduce treatment costs dramatically, and can 
potentially save lives. 
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1.2.3 Shunt surgery as main treatment and problems after shunt 
surgery 
 
a. Shunt surgery as main treatment 
The most common treatment to manage hydrocephalus medically 
is insertion of the shunt system which consists of two catheters and an 
one-way valve as shown in Figure 1-13. The ends of the catheter connect a 
space within a ventricle and another space within the abdominal (or 
peritoneal) cavity in which negative pressure is generated. A valve along 
the catheter is a one way valve that drains excessive CSF from the brain, 
and the shunt regulates the flow or pressure of CSF from the ventricles. A 
reservoir is located in the shunt or added as a component, and this 
reservoir allows CSF to be extracted for testing purposes as shown in 
Figure 1-13(a). Valve types available are categorized according to the 
medical condition. The fixed pressure valves include a single valve 
mechanism that regulates the shunt flow rate. The valves are typically 
available in three pressure ranges: low, medium or high. The adjustable 
valve includes a mechanism that can be non-magnetic tools. This gives the 
doctor the ability to change the valve pressure setting in the office without 
using a surgical procedure. 
Figure 1-14 shows how to implant the shunt system.  In the 
surgical process, a U-shape surgical cut is made near the top of the head. 
Another cut is made in the belly. A small hole is drilled in the skull. A 
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Figure 1-13. A shunt system. (www.medtronic.com); (a) shunt components 
and valve functions, (b) fixed pressure valve with overdrainage protection 
and cutaway, and (c) adjustable valve that can be adjusted to difference 
pressure settings for surgery and cutaway.  
Distal 
Catheter
Valve
Ventricular 
Catheter 
(a) 
(b) 
(c) 
Valve pumping 
CSF sampling 
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(b) 
(a) 
(c) 
Figure 1-15. Brain scanned images (CSF: dark color),  of enlarged 
ventricles before shunt insertion and normal ventricles after shunt 
insertion; (a) CT images, (b) ultrasound images, and (c) MRI images. 
(www.hydroassoc.org) 
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catheter is passed into a ventricle. Another catheter is placed under the 
skin behind the ear and moved into the peritoneal cavity. A valve is placed 
underneath the skin behind the ear. The valve is attached to both catheters.  
Figure 1-15 shows brain scanned images taken from (a) CT, (b) ultrasound, 
and (c) MRI methods. Left images show enlarged ventricles before shunt 
insertion and right images show normal ventricles after shunt insertion.  
CSF enters the shunt system through small holes near the tip of the 
proximal catheter and flows into the peritoneal cavity. After inserting the 
shunt, it was examined that ventricles were normal. 
 
b. Problems after shunt surgery 
Over 40,000 shunt surgeries are performed every year in the US. 
Although the shunt systems have been evaluated by new technologies, the 
shunt system is not perfect in terms of the medical care. The 
inconvenience, financial cost, psychological problem, and shunt failure 
present major issues associated with the shunt system. The failure rate for 
all implanted shunts is as high as 40% by 1 year and 50% by 2 years. This 
failure rate stems from several shortcomings. The most common reasons 
for the failure of the shunt system are [22]:  
①. Obstruction  
②. Mechanical failure.  
Obstruction is the flow interruption through the shunt due to 
occlusion of the shunt lumen. Mechanical failure is caused by one of the 
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following: a fracture of the distal tubing, disconnection of shunt 
components, migration of the intraventricular catheter after initial 
insertion, misplacement of a ventricular catheter, and misplacement of a 
distal catheter. Less common reasons are as follows [22]:  
①. Overdrainage and underdrainage 
②.  Loculation (isolated segments of ventricle) 
③. Abdominal complications (pseudocyst:loculated 
intra-abdominal fluid collection)  
These problems after shunt surgery result in additional operation in 
half of all patients with the shunt system within two years and significant 
monetary cost. 
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1.3 Our approach for the treatment of hydrocephalus 
Currently, hydrocephalus is treated by a surgical procedure, in 
which a tube/valve device shunts excess CSF from the intracranial 
compartment to another location. The shunt systems currently in use was 
initially developed in 1950’s and has remained essentially unchanged for 
over 50 years. Although the shunt systems have prevented death and 
disability from hydrocephalus, they still have persistent shortcomings. The 
current shunt systems have a very high failure rate (~50%) within two 
years after implantation mainly due to occlusion by debris, blood clot or 
infection. Other causes of failure include tubing breakage, kinking or 
shortening due to patient growth or movement. Another significant 
shortcoming of the shunt system is imprecise shunting such as over and 
under shunting. According to the National Inpatient Sample database for 
the year 2000, there were 5,574 patients who had a shunt either inserted, 
revised, or removed. The total cost was $1.1 billion in the United States. 
Ventricular shunts as primary procedures constitute a significant medical 
and economic problem [23].  
We propose an innovative approach for the treatment of hydrocephalus 
which can address the problems of the current treatment as shown in 
Figure 1-16. The goal of this research is to develop an implantable 
microdevice that diverts excessive CSF from the subarachnoid space to the 
sagittal sinus. We are attempting to replace the deficient arachnoid 
granulations (AG) that produce the pathologic condition of 
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communicating hydrocephalus with an artificial device equivalent to 
restore the normal absorptive function. The implantable microfabricated 
arachnoid granulations (MAG) consist of an array of hollow 
microneedles and corresponding passive microvalves. The microneedle 
array will be surgically placed to pierce the dura mater to act as a one-way 
conduit for CSF. Microvalves attached to the microneedles regulate the 
CSF flow into the sagittal sinus in response to the pressure differential 
between the sinus and the subarachnoid space just like normally 
functioning AG. Therefore, the proposed device will more closely mimic 
the physiologic CSF dynamics. The proposed MAG will open a new era in 
the treatment of hydrocephalus. 
We present an upgraded PDMS/Parylene microvalve that has a 3-
D dome petal shape for the treatment of hydrocephalus. This valve design 
was inspired from a PDMS valve used in condiment bottles (e.g. French’s 
mustard source bottle). The thin PDMS valves have a dome shape with 
cross-cut opening such that the fluid cannot flow out until pressure is 
generated by squeezing the plastic bottle. Microfabrication techniques 
were applied to miniaturize the valve for our application. Previously we 
reported a Parylene micro valve [2]. However, the valve failed to prevent 
reverse flow and maintain its shape during flow test. This was mainly due 
to the relatively flat (non-hemispherical) geometry and the non-sticky 
nature of Parylene. Therefore, we present the use of a PDMS/Parylene 
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Figure 1-16. Schematics of microfabricated arachnoid granulation 
(MAG)  
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Figure 1-17. A schematic diagram of opening and closing mechanism
of the PDMS/ Parylene microvalve with 3-D dome petal shape. (a) P1 >
P2 : close  and (b) P1 < P2 : open. 
PDMS 
(a) (b) 
P2 
P1 
P2 
Parylene 
P1 
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composite microvalve. By adding a PDMS layer, the self-sealing property 
of the valve membrane was greatly improved. Novel microfabrication 
techniques have been developed to build the proposed PDMS/Parylene 
microvalve that has 3-D dome shape geometry.   
Figure 1-17 shows a schematic diagram of how the valve works. 
When the internal pressure (P2) is greater than the external pressure (P1), 
the pressure difference causes the microvalve to open. On the other hand, 
when P1 is greater than P2, the valve is closed and sealed.  
Figure 1-18 shows to compare conventional shunt system and our 
microfabricated device. Shunt systems divert CSF from SAS to Peritoneal 
cavity but our MAG diverts CSF from SAS to SSS just like normal 
arachnoid granulations. Shunts consist of a single valve and two long 
catheters while our MAG consists of an array of 100 devices. Therefore, 
even if some of the devices experience occlusion, the system can still 
function and divert CSF. Also, since our MAG does not have long 
catheters and works based on the pressure difference between SAS and 
SSS, the problems of the shunt systems such as occlusion, infection, and 
mechanical failures can be minimized or eliminated. Finally, unlike the 
bulk shunt systems, our MAG is a tiny device. 
To implant the device on the dura mater and build the channel for 
the flow of CSF through the dura mater, a microneedle with the channel 
should puncture the dura mater tissue. This microneedle is made of SU-8. 
SU-8 is commonly used as epoxy based negative photoresist. It is one of 
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the most biocompatible materials used in bio-MEMS. A major 
consideration is an optimal balance of sharpness and strength to puncture 
the dura mater.  
This dissertation presents the design, fabrication, and testing of the 
implantable microdevice for the treatment of Hydrocephalus. Design 
optimization of the microvalve has been performed through numerical 
simulation study using COMSOL software. Prototype models were 
fabricated using microfabrication techniques such as photolithography, 
thin-film deposition, diffuser lithography, reactive-ion etching and 
excimer laser machining. A variety of tests including in vitro and in vivo 
tests with fabricated devices have been performed.  
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Shunt MAG 
 From SAS to peritoneal cavity 
 Implanted under the skin 
Single valve & two long catheters  
Problems (Occlusion, infection, 
mechanical failures) 
Bulky system  
From SAS to SSS (Physiological) 
Implanted under the skull  
Array of 100 devices, no catheter 
Most of the problems of VP shunts 
are addressed  
Small device  
 
 
 
 
 
 
 
 
Figure 1-18. Shunt vs. MAG 
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1.4 Specific Aims 
 
1.4.1 Aim 1: Design, simulate, fabricate, and test an array of one-
way microvalves. 
Comsol Multiphysics software was applied to the 3-D simulation 
of a microvalve for accurate predition of valve performance and design 
optimization. Several microfabrication techniques such as dome-shaped 
SU-8 mold fabrication, PDMS/Parylene coating, and laser machining for 
valve opening were investigated to build the proposed microvalve with 
which the valve performance test was done. The pressure-drop vs. flow 
rate characteristics of the fabricated microvalve was investigated through 
in-vitro flow tests of a 10x10 microvalve array with each microvalve 
having a 210 μm diameter and three kinds of opening shapes. The 
simulated data was compared to experimental data to validate the design 
parameters. This work towards accomplishing Aim1 was described in 
Chapter 2. 
 
1.4.2 Aim 2: Design, simulate, fabricate, and test an array of 
microneedles. 
In order to design the channel size inside the microneedles, 
pressure drop through the channel was considered and calculated not to 
affect the valve performance using the comsol Multiphysics program. We 
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employed the SU-8 microneedle fabrication process reported by Choi et al. 
[2].  The microneedles were fabricated through a three-step process: UV 
light scattering in a thick SU-8 layer for generating a tapered 
microstructure, RIE process for sharpening the tapered microstructure, 
and Ti coating for improving the strength. In order to find an optimal 
balance of strength and sharpness, the puncture tests were performed on 
pig’s dura mater which is very similar to human’s dura mater and will be 
used in in-vivo test. The biocompatibility test was performed to check the 
channel blockage due to the platelets adhesion. This work for Aim 2 was 
described in Chapter 3. 
 
1.4.3 Aim 3: Assemble an array of microvalves and an array of 
microneedles into MAG (Micro-fabricated arachnoid 
granulation), and perform in-vitro flow test and 
biocompatibility test. 
A microvalve array will be aligned and bonded with a microneedle 
array. In-vitro flow test and biocompatibility test will be performed with 
fabricated MAG before in-vivo testing of this device in a pig. This work 
for Aim 3 was described in Chapter 4. 
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CHAPTER 2: AN ARRAY OF PDMS/PARYLENE MICROVALVES 
 
2.1 Review of microvalve array for biomedical applications 
The innovative treatment of hydrocephalus is to implant a 
biocompatible micro check valve mimicking the function of AG. The 
microvalve for this approach requires following conditions; biocompatible 
and nontoxic material, ease fabrication, and proper valving functions such 
as minimal cracking pressure, high backward flow resistances, and 
sufficient forward flow (~ 0.4 ml/min at CSF pressure of 1500 Pa).  
Several implantable microvalves have been presented for 
biomedical applications. Chung et al. (2003) developed a MEMS-based 
CSF shunt microvalve consisting of flow nozzles with a 6 μm thick 
parylene membrane connected to an anchor by bridges [1, 2]. The function 
of this valve can be precisely controlled by the selection of the design 
parameters. The dimension of the assembled CSF shunt valve is 
2.5x2.5x0.8 mm3. The pressure acting on the valve is generated by a finger 
pushing on the outer housing. A maximum displacement of 72 μm and 
maximum resistible pressure up to 4 kPa were observed. Figure 2-1 shows 
schematics of CSF shunt system in function. In pushing phase, CSF shunt 
valve is pumped down to abdominal cavity. In restoring phase, CSF is 
sucked from brain to the inner cavity of CSF shunt system. Since this 
microvalve should be operated using a finger, this valve can’t be 
implanted for our application. Chen et al. (2007) proposed surface-
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Figure 2-1. Schematics of CSF shunt system in function. In pushing 
phase, CSF shunt valve is pumped down to abdominal cavity. In 
restoring phase, CSF is sucked from brain to the inner cavity of CSF 
shunt system. 
P1 
P2 
P1 P1 
P2 P2 
CSF shunt valve 
CSF shunt valve 
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Figure 2-2. Concept of dual-valved microflow regulation. (a) target 
flow regulation profile, (b) a back-to-back configuration of dual valves, 
and (c) regulation profile of dual-valved microfluidic system.  
(a) 
(b) 
(c) 
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micromachined parylene dual valves for on-chip unpowered microflow 
regulation [3, 4]. This back-to-back dual-valved configuration requires 
only two in-channel check valves which consist of a normally closed valve 
in forward flow operation at the inlet and a normally open valve in 
backward flow operation at the outlet of a microchannel. The dual 
microsystem was able to regulate pressure in the range of 0~1 psi with 
measured flow rates of up to 0.7 mL/min for air flow and 1.3 μL/min for 
water flow. Figure 2-2 shows the concept of dual-valved microflow 
regulation. Figure 2-2 (a) is an ideal bandpass profile of dual valves, (b) is 
a schematic view of dual valves, and (c) is the regulation profile of dual-
valved microfluidic system. A microvalve for our application should be 
working sensitively with the increase of incranial pressure. This 
microvalve can’t be adapted to our application because a valve is closed in 
the pressure range over cut-off point by outlet NO valve as shown in 
Figure 2-2(c). Emam et al. (2008) presented an array of implantable one-
way microvalves for the treatment of hydrocephalus [5]. This parylene 
microvalve can control flow based on pressure differential. Initial flow 
tests demonstrated the desired low cracking pressure of the valve and a 
sufficient mechanical stability. As this valve does not have a backward 
flow resistance, this microvalve can’t be applied to our application. Cheng 
et al. (2008) reported a transcutaneous controlled magnetic microvalve 
based on iron-powder filled polydimethysiloxane (PDMS) for implantable 
drug delivery systems, which allows transcutaneous control when it is 
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Figure 2-3. Schematics of the mignetic microvalve closed normally 
and opened by a permanent magnetic. 
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Figure 2-4. (a) Full glaucoma drainage device (GDD) system 
consisting of a dual-valve microflow regulation system, a parylene 
tube carrier, and a rollable/foldable anchor (NO: Normally Open, NC: 
Norally Closed) and (b) Subconjunctival implantation concept of 
GDD.  
(a) 
(b) 
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implanted under the skin [6]. Only a magnet is required to work the 
microvalve for drug delivery. Figure 2-3 shows schematics of the 
magnetic valve closed normally when there is no magnetic force applied 
and opened by a permanent magnetic. This valve can’t be employed in our 
application because of an external force which can’t be acceptable for our 
application. Lin et al. (2009) presented a 20 μm thick parylene-enabled 
microvalved shunt implant for glaucoma drainage. This shunt has dual 
back-to-back microvalves (open at 20 mmHg and closed beyond 50 
mmHg) inside the tube [7]. The dual-checkvalve operation enables this 
device to physically drain the extra intraocular fluid and regulate the 
intraocular pressure within the normal range (15~20 mmHg). This valve is 
the first implanted checkvalved glaucoma drainage device (GDD) for the 
treatment of glaucoma, which is passive, consumes no additional power, 
and functions without any circuit board involved to pursue its medical 
application. The working mechanism of this dual valve is the same as that 
of Cheng’s valve. Figure 2-4 shows that (a) is the glaucoma drainage 
device system consisting of a dual-valve microflow regulation system, a 
parylene tube carrier, and a rollable/ foldable anchor and (b) is a 
subconjunctival implantation concept of glaucoma drainage device. As the 
valve is closed beyond 50 mmHg this microvalve can’t be used for our 
application. 
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2.2 Design of an array of microvalves using 3D simulation 
 
2.2.1 Design criteria for microvalve 
1. It should be an array type for minimizing the chances of device 
failure. 
2. It should be an one-way, passive valve which should function 
based on pressure differential. 
3. It must have a very low cracking pressure (< 10 mmH2O) and 
high backward flow resistance (no flow up to 200 mmH2O): 
normally closed valve. 
4. It needs to be small (< 5x5x1 mm3) but not too small for surgical 
implantation. 
5. The valve material needs to be biocompatible to minimize blood 
clotting and any damage to the tissue. 
6. The device should be cost-effective and is preferably made of 
polymer. 
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2.2.2 Selected designs and materials 
We have proposed two designs for microvalve. One is a dome-
petal design and the other is a corrugated spring design. The dome-petal 
design uses its geometric effect to open and close. The corrugated spring 
design as shown in Figure 1-18. This idea came from silicon valves in 
condimental bottles such as French’s bottle. The corrugated spring design 
is a typical diaphragm valve. This design as adopted from literature review 
as an alternative design. The reason why we chose the dome-petal design 
as our primary valve design was not only because it was a unique design 
but because it requires only ine photomask process.  
In terms of valve material, we chose PDMS/Parylene composite. 
PDMS is polydimethysiloxane. It is silicon elastomer. We picked it 
because its sticky nature can provide a good self-sealing ability and 
because it is biocompatible and micro-manufacturable. Parylene is 
polyparaxylylene. It is a thin film polymer deposited from gas phase. We 
picked it because it can provide mechanical rigidity to the valve. Parylene 
is also known to be biocompatible.  
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2.2.3 Design and simulation of an array of micrvalves 
In order to be capable of diverting cerebrospinal fluid equivalent to 
normally functioning arachnoid granulation, 3-D dome petal shape was 
employed as our check valve design. This shape enables the check valve 
to open and close easily. The normally open valves stay open until the 
pressure reaches a certain point which the membrane collapses and covers 
the orifice. With this reason, the normally closed valve design was chosen 
to minimize the backward flow. Thin polymer films, PDMS and Parylene 
were chosen as the valve material to achieve the low cracking pressure 
required for our application.  
Multiple arachnoid granulations exist in the dura mata membrane 
of the brain. In order to mimic this design and also avoid device failure 
due to valve blockage, 7x7 and 10x10 arrays of microvalves were 
designed with an area of 5x5 mm2. In order to simulate native arachnoid 
granulations, the valve must operate at relatively constant rate of 0.3~0.5 
ml/min at a pressure range of 500 to 1500 Pa with no backward flow. The 
main design parameters that determined the valve performance are listed 
in Table 2-1. The thickness of Parylene C was fixed as 10 μm in order to 
provide the rigidity on a PDMS layer while the thickness of PDMS was 
varied. As minimum size of the laser beam is 6 μm, the opening gap was 
fixed as 6 μm. Two microvalves were designed. Five different opening 
shapes such as slit cut, cross cut, and combined cut were investigated for 
those microvalves.  In order to validate and optimize design, 3-D 
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numerical simulation study was conducted. The COMSOL software was 
used to analyze the fluid-structure interaction with the coupling between 
fluid and a dynamic microvalve. Figure 2-5(a) is the three-dimensional 
simulation model. The size of the simulation space is 500 μm x 500 μm x 5 
mm. A microvalve is located in the middle separating the space into two 
parts, superior sagittal sinus (top) and subarachnoid area (bottom). The 
dimension of the dome shaped microvalve is shown in Figure 2-5(b) and (c). 
In the simulation only a Parylene layer was considered because including a 
thin PDMS layer requires numerous meshes and consequently extremely 
high computation capacity. Since the Young’s modulus (3.2 GPa) of 
Parylene C (density=1310 kg/m3, Poisson’s ratio=0.4) is much higher than 
that (0.5 MPa) of PDMS, the motion of a microvalve depends primarily on 
the Parylene layer. For the fluid, the property of water (density=1000 kg/m3, 
dynamic viscosity=0.001 Pa·s) was used in the simulation. 
Three multiphysics of Solid Stress-Strain, Moving Mesh, and 
Incompressible Navier-Stokes were coupled in the simulation. Fully 
developed laminar flow generated the force distribution on the microvalve 
resulting in the displacement of the microvalve. This motion had direct 
influence on the development of the flow again using the moving mesh 
method. In Solid Stress-Strain modeling, an elastic formulation and a 
nonlinear geometry formulation were applied for large deformation. The 
square edge boundaries of a microvalve were fixed to the wall. Other 
boundaries experience a fluid load as a force sum of pressure and viscous 
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flow. The governing equation is 
)))((( TuupInF                 (1) 
where n is the normal vector, p is the pressure, I is the unit diagonal matrix, 
η is the dynamic viscosity, and u is the velocity.  In Moving Mesh modeling, 
the arbitrary Lagrangian-Eulerian (ALE) method handles the dynamics of 
the deforming microvalve and the moving boundaries with a virtual moving 
grid. It generated new mesh coordinates on the channel based on the 
movement of the boundaries of the microvalve. It reformulates the 
Incompressible Navier-Stokes equation to solve the flow as follows; 
0,)()))(()((  uFuuuuIp T        (2) 
where ρ is the fluid’s density and F is the volume force affecting the fluid. 
All wall boundary conditions are no slip except zero pressure at the outlet 
and positive pressure at the inlet.  
In the mesh generation, predefined mesh size was set to Normal.  
Maximum element sizes for the microvalve and the fluid were set to 5e-6 m 
and 1e-4 m. GMRES and Incomplete LU were used as a parametric 
segregated solver.  
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                   Table 2-1. Design parameters of the microvalve. 
 
Design parameters 
 
 
Value 
Dome diameter (D) 170 μm, 210 μm 
Dome height (H) 80 μm, 100 μm 
 
Parylene C thickness 
 
10 μm 
 
PDMS thickness 
 
Variant range (Figure 2-7) 
 
Opening gap (G) 
 
3 μm (defined by laser) 
         Opening shape Cross-cut, slit-cut, combined 
Opening lengths (L1, L2) 
         170 μm, 210 μm 
    (Cross-cut and Slit-cut) 
        L1=210 μm, L2=30, 60 μm 
          (Combined-cut) 
D 
L1 
L2      G
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Figure 2-5. 3D simulated geometry, dimensions, and boundary 
conditions: (a) total view, (b) top view of a microvalve, and (c) 
side view of a microvalve. 
(b)
(c)
500 μm 
60 μm
200 μm 
Gap 
(a) 
5 m
m
 
Inlet 
Outlet 
Wall 
0 
1 
2 
-1 
‐2 
D 200 μm
100 μm
10 μm thick Parylene
0  
Fixed
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2.2.4 Results and discussion 
Figure 2-6(a) and (b) show the 3-D plots for velocity, displacement, 
and von Mises stress when the gap and the inlet pressure are 3 μm and 
1300 Pa. Maximum von Mises yield strength is 0.721 MPa at the corner of 
dome. This value is much lower than the yield strength (=65.5 MPa) of 
Parylene C. As PDMS is more flexible than Parylene, the maximum 
displacement of a microvalve is decided by Parylene. These results prove 
the safety and durability of a microvalve without mechanical failure. In 
Figure 2-6(a), the percentage rate of valve displacement to gap size at 
1300 Pa is 4%. The valve displacement is very small against our 
expectation. Perhaps, the reason is why a stiff parylene layer is dominant 
in the valve displacement. 
 Average velocity (=2.56e-4 m/s) at 1300 Pa can be achieved by 
averaging all values from the slice plot for velocity in Figure 2-7. Flow 
rate (=0.0038 ml/min) for single microvalve can be calculated by 
multiplying average velocity and square area (500 μm x 500 μm) together. 
Multiplying this flow rate by 100 (total number of microvalves) becomes 
the flow rate (=0.38 ml/min) for an array of 10x10 microvalves. A plot of 
pressure difference vs. flow rate, as shown in Figure 2-7, was made by 
repeating this calculation based on the simulation of two microvalves with 
3 and 4 μm gaps. The simulation result shows that the flow rate is 
apparently very sensitive to the gap size. Both valves with 3 and 4 μm 
gaps work in the desired working zone under forward flow. However, the 
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valve with 3 μm gap is expected to have higher resistance than that with 4 
μm gap under backward flow due to smaller gap.  Simulated data has a 
good agreement with experimental data at a 3 μm gap under forwardward 
flow.  This result indicates the validation of this simulation which can be 
qualified as a tool for the microvalve design.  
74 
 
 
 
Figure 2-6. Simulated plots for: (a) velocity (slice and arrow) and 
displacement at Pin=1300 Pa and (b) von Mises stress and velocity 
(arrow) at Pin=1300 Pa. 
(a) 
(b) 
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Figure 2-7. Simulated plots for pressure difference vs. flow rate at 3 
and 4μm gaps. 
Pressure difference 
[Pa] 
Flow rate 
 [ml/min] 
Simulated data (4 μm gap) 
Simulated data (3 μm gap)
Experimental data (3 μm gap) 
Desired working zone 
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2.3 Fabrication of an array of microvalves 
 
2.3.1 Fabrication process 
Figure 2-8, 2-9, and 2-10 show the fabrication process flow of 
PDMS/Parylene dome petal microvalve. The three main fabrication 
processes are dome-shaped SU-8 mold fabrication, PDMS and Parylene 
coating on the mold, and Excimer laser machining for valve opening.  
In Figure 2-8, first, a dome-shaped SU-8 mold was fabricated by 
diffuser lithography technique based on light scattering through diffuser 
glass. Initially, a thin SU-8 2002 layer was spin-coated on a Cr patterned 
glass plate and exposed to UV, effectively acting as an adhesion promoter 
for subsequent fabrication steps. Then a thick SU-8 2035 layer was spin-
coated on top. This substrate was then flipped over and a diffuser glass 
with one side of Opal (NT43-719, Edmond Optics Co., Ltd, Barrington, 
NJ) as placed on the Cr plate followed by UV exposure, post-exposure 
bake, and developing. This process produced dome-shaped SU-8 molds as 
shown in Figure 2-8(a). The dome diameter on the fabricated SU-8 mold 
is a little larger than the diameter of Cr patterned circles due to the light 
scattering. 
Then, the SU-8 mold was silanized prior to PDMS/Parylene 
deposition for easy release. PDMS was diluted with hexane (PDMS: 
Hexane=1:1) and was spin-coated on the SU-8 mold at 1000 rpm for 20 
sec. The mold was then kept upside down at room temperature for 
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Figure 2-8. Fabrication process flow for dome-shaped SU-8 mold. 
Glass 
Patterned Cr plate
Spin-coat SU-8 2035
SU-8 mold
Spin-coat SU-8 2002
Glass 
UV Exposure
Glass 
Glass 
Finished SU-8 mold 
Glass 
Diffuser glass with Opal 
UV Exposure through diffuser glass 
Opal  
Glass 
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Figure 2-9. PDMS and Parylene deposition process. 
Finished composite layer
PDMS & Parylene layer
Parylene C deposition
Glass 
PDMS Reflow and bake
Glass 
Spin-coat PDMS dilution
Glass 
Silanization
Glass 
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Figure 2-10. Excimer laser machining process and microscopic images of 
fabricated microvalves: (a) D=170 μm & Cross cut (170 μm x 170 μm), (b) 
D=170 μm & Slit cut (170 μm), (c) D=210μm & Slit cut (200 μm), (d) D=210
μm & Combined cut (200 μm x 30 μm), (e) D=210 μm & Combined cut (200 
μm x 60 μm) , and (f) 10x10 array of microvalves with (e). 
Excimer laser machining
PDMS/Parylene membrane
(a) (b) 
(c) (d) (e) 
Wrinkles
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2.5 or 5 hours to induce PDMS reflow and to form a uniform layer prior to 
baking (70oC, 30 min). A 10 μm thick Parylene layer was then deposited 
on the PDMS coated with the SU-8 mold (Figure 2-9).  
Finally, KrF excimer laser machining (RAPID X250; Resonetics 
Co, Ltd, Nashua, NH) was done to make valve opening with cross-cut and 
slit-cut shapes on the composite layer of PDMS and Parylene released 
from the SU-8 mold. A beam diameter of approximately 5 μm was used 
for this process. Dome diameters of array type were 170 and 210 μm (The 
original Cr pattern diameters were 150 and 200 μm, respectively). Five 
kinds of opening shapes listed in table 1 were generated. Figure 2-10(a) 
and (b) show opening shapes generated on the dome with 170 μm 
diameter. Figure 2-10(c)~(e) show opening shapes generated on the dome 
with 200 μm diameter. The ablation gap size of the valve was about 3 μm. 
Figure 2-10(f) is a finished 10x10 array of microvalves with (e) shape. 
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2.3.2 Results and discussion 
Figure 2-11 shows a cross-sectional SEM picture of a microvalve 
which has a 210 μm diameter and experienced 5 hr PDMS reflow. This 
side view was generated by laser ablation with 5 μm beam diameter along 
each dome’s center accross a 10x10 array. This dome shape is more 
spherical compared to the relatively flat shape which we suggested 
previously. The thickness of Parylene was found to be a uniform 10 μm in 
all areas. The thickness of PDMS varies according to the location of the 
dome. The thickness between corner and top is about 1.5 μm. The 
thickness near top area is about 3 μm. The PDMS thickness outside of the 
dome is about 70 μm. 
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Figure 2-11. SEM image: cross-sectional view of a microvalve (D=210 μm 
and 5hrs reflow). 
Top 
Corner 
PDMS 
Parylene 
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2.4 Investigation for wrinkle phenomena 
 
2.4.1 Sample preparation for wrinkle test 
In the PDMS/Parylene composite layer, the Parylene layer 
provides the mechanical rigidity necessary for release process (thin 
PDMS layer without Parylene was torn during the release process) while 
PDMS can still maintain its surface properties such as observation is that 
lots of repeated wrinkles were observed on the PDMS/Parylene 
composite layer as shown in Figure 2-4.  
The wrinkle size and frequency varied as a function of the ratio 
(PDMS: Parylene) of the thickness of the two layers. No wrinkle was 
observed on the dome membrane where PDMS and Parylene have 
comparable thicknesses while lots of wrinkles were found on the base 
membrane where PDMS is much thicker (70-100 µm) than Parylene (10 
µm). The wrinkle formation seems to be due to the mechanical rigidity 
mismatch between elastic PDMS and rigid Parylene layers which likely 
created wrinkles to relieve the stress.  
For better understanding of this wrinkle issue, ten samples listed 
on Table 2-2 have been prepared. Each sample has one or two layers 
coated on the 2x2 glass (1.65 mm thick) or thick PDMS blocks. The 
thickness of these layers varies. These samples were investigated under 
optical microscope. 
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Sample # Substrate Middle layer  Parylene C  Wrinkle 
1 2x2 Glass No 10 μm None 
2 2x2 Glass Thin SU-8 2005 at 
1000 rpm 
10 μm None 
3 2x2 Glass 40 μm thick PDMS 10 μm Wavy 
4 2x2 Glass  20 μm thick PDMS 10 μm Dots 
5 PDMS block No 10 μm None 
6 2x2 Glass No 2 μm None 
7 2x2 Glass Thin SU-8 2005 at 
1000 rpm 
2 μm None 
8 2x2 Glass  18 μm thick PDMS 2 μm Dots 
9 2x2 Glass   8 μm thick PDMS 2 μm Wavy 
10 PDMS block No 2 μm None 
 
 
   
Middle layer
Parylene C
Glass or PDMS block
Table 2-2. 10 kinds of samples prepared for the investigation of the wrinkle issue 
85 
 
2.4.2 Results and discussion 
Figure 2-12 shows repeated wrinkles without delamination which 
were observed on only the samples of #3, 4, 8, and 9. The reason is that 
wrinkles occur on a film which requires coherent deformation of a soft 
material. The proof is that these samples included a thin film of Parylene 
and a layer of soft material, PDMS on the glass.  
Wave wrinkles were generated on sample #3 and sample #9 with 
the thickness ratio of 4:1 while dotted wrinkles were found on sample #4 
(thickness ratio=2:1) and sample #8 (thickness ratio=9:1). This 
phenomenon may refer to the thickness ratio as main factor for wrinkle 
generation. However, even though sample #3 has the same thickness ratio 
as sample #9, the wrinkle width of sample #3 is twice as large as those of 
sample #9. This result may indicate that both of the thickness and the 
thickness ratio are related with wrinkle generation. Based on this 
relationship, the case of sample #3 and #4 can be explained with thicker 
PDMS layer which is vertically more compliant. Thicker PDMS enabled 
sample #3 to be developed furhter. In addition, as wrinkles were not 
developed fully on samples with the ratio out of 4:1 based on this 
investigation, the thickness ratio of 4:1 may be close to a critical point 
which causes maximum wrinkle generation.  
From the literature review on this phenomena, we learned that if a 
rigid plate is subjected to stress and attached to a soft elastic medium, it is 
very likely that this stress is relieved by wrinkling: The composite plate 
86 
 
Figure 2-12. Wrinkles (20x magnification): (a) sample #3 (wave 
width=10 μm), (b) sample #4, (c) sample #8, and (d) sample #9 (wave 
width=5 μm). 
(a) (b) 
(c) (d) 
10 μm 
5 μm 
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buckles into a large number of waves and the pattern and size of the 
wrinkles depend on the thickness of the materials as well as the thickness 
ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
2.5 Flow characterization for the performance of the microvalve 
 
2.5.1 Flow test 
Flow tests were performed using deionized water in order to 
characterize the performance of the microvalves. Differential pressures 
between the top and bottom sides of the microvalve were measured under 
various flow rate conditions. The range of pressure difference measured 
in this test was between 0 and 8 kPa at a flow rate of up to 0.8 ml/min. 
Figure 2-13 shows the test set-up consisting of a PDMS flow chamber 
where an array of microvalves is placed, a pressure transducer (max. 1 psi, 
OMEGA Co., Ltd, Stamford, CT), a read-out, and a syringe pump. Both 
sides of the microvalve were tightly fixed to the test chamber using a 
PDMS gasket to ensure sealing. Pressure difference for forward and 
backward flows was measured after the flow reached steady-state. To 
obtain reverse flow data, the valve was simply switched to the opposite 
direction. It was found that this orientation change occasionally caused 
bubbles to form inside the tubing. These bubbles were found to have a 
profound influence on the flow characteristics and failure rates of the 
device and were removed prior to testing. The flow test was repeated five 
times for measuring the characteristics of each valve. All valves were not 
deformed after several tests. 
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2.5.2 Results and discussion 
Figure 2-14 shows the flow test results from three different kinds 
of microvalve array with 170 µm diameter:  
(a) 5hr reflow and cross-cut opening (170 μm x 170 μm), 
(b) 2.5hr reflow and cross-cut opening (170 μm x 170 μm), 
(c) 5hr reflow and slit-cut opening (170 μm). 
These were all from an array of 7x7 microvalves. The slope of the plot is 
inversely proportional to the flow resistance. In other words, a higher 
slope indicates a lower flow resistance. The flow slope of the case (b) was 
approximately 0.04 µl/Pa·min, which was about 32 times higher than a 
single microvalve (data not shown).  Note that the single device had 
slightly larger diameter (210 µm) than the array valves (170 µm). By 
comparing curves (a) and (c), the effect of valve opening shape may be 
observed. Cross-cut opening provides more flexibility to the valve 
membrane than the slit-cut opening. Consequently, the microvalve with a 
cross-cut opening can be cracked open more easily under forward flows 
and have less flow resistance than slit-cut valve. It is also shown that slit-
cut opening provides a better sealing and higher flow resistance under 
backward flows. Therefore, the slit-cut opening microvalve has better flow 
rectification performance while the cross-cut opening microvalve provides 
lower cracking pressure and more flow rates during forward flows. 
The effect of PDMS reflow time can also be analyzed by 
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Figure 2-14. Flow test results for 7x7 array microvalves with 170 μm 
diameter: (a) 5hr reflow and cross-cut opening (170μm x170μm), (b)
2.5hr reflow and cross-cut opening (170μm x170μm), and (c) 5hr 
reflow and slit-cut opening (170 μm). 
(a) (b)
(c)
Flow rate 
[ml/min] 
Pressure difference 
[Pa] 
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comparing curves (a) and (b). The microvalve made by 5 hr reflow shows 
a lower flow resistance than 2.5 hr reflow case in both forward and 
backward flow conditions.  This is probably due to the thickness variation 
of PDMS layer as a function of reflow time. 5 hr reflow would be 
sufficient for the formation of a uniform PDMS layer while 2.5 hr may 
result in non-uniform thickness with thick layer at the bottom and thin 
layer at the top of the microvalve. This non-uniform PDMS layer may 
result in higher flow resistance for 2.5 hr reflow microvalves.   
An ideal microvalve for the treatment of hydrocephalus needs to 
have a cracking pressure close to zero, a forward flow rate of 0.3~0.5 
ml/min at pressure differences between 500 and 1500 Pa.  Although none 
of the microvalves presented in Figure 2-14 met all the requirements, 
some insight could be obtained from the data.  Basically, slit-cut opening 
provides a better flow rectification (better sealing in backward flows) and 
cross-cut opening provides a higher flow rate in forward flows. One way 
to increase the forward flow rate of the slit-cut valve without decreasing 
its self-sealing performance may be to increase the opening length. 
Another way is simply to increase the number of valves (e.g. 10x10 array 
instead of 7x7 array). 
Above-mentioned recommendations such as larger diameter in 
valve size, more microvalves, and modified opening shape were applied to 
10x10 array microvalves. The flow test results from three kinds of 10x10 
array microvalves with 210 μm diameter are pictured in Figure 2-15: 
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Figure 2-15 Flow test results for 10x10 array microvalves with 210 μm
diameter: (a) 5hr reflow and cross-cut opening (210μm x60μm), (b) 5hr
reflow and cross-cut opening (210 μm x30μm), and (c) 5hr reflow and
slit-cut opening  (210μm). 
Pressure difference 
[Pa] 
Flow rate 
[ml/min] 
(a) (b)
(c) 
Desired 
working 
zone 
94 
 
(a) 5hr reflow and combined-cut opening (210 μm x 60 μm), 
(b) 5hr reflow and combined-cut opening (210 μm x 30 μm), 
(c) 5hr reflow and slit-cut opening (210 μm).  
The slope of curves (a), (b), and (c) in Figure 2-15 were found to 
be 0.25, 0.15, and 0.02 µl/Pa·min respectively. The maximum error range 
of averaged difference pressure is about ±6% at low pressure differentials 
and about ±2% at high pressure differentials. Small variance of error range 
proves that the microvalves are mechanically stable during the flow test. 
By comparing (a), (b), and (c), the slopes of curves (a) and (b) are much 
larger as compared with curve (c). This means that a 10x10 array 
microvalve with slit-cut opening has much higher forward flow resistance 
than curves (a) and (b) types. As the cross opening length (60 μm) of 
curve (a) is larger than the combined opening length (30 μm) of curve (b), 
the flow slope of curve (a) is almost twice as large as that of curve (b) at 
the same pressure difference. The flow test was repeated five times for 
every microvalve. Additionally, the mechanical integrity of the microvalve 
array was maintained after flow testing without any plastic deformation, 
making them suitable for long term in vivo use. 
In Figure 2-15, all opening shapes provide very high flow 
resistance to the backward flow in the range of zero to -2500 Pa. High 
flow resistance is due to short slit cut (0, 30, and 60 μm) crossing long slit 
cut (200 μm) and a PDMS layer on top area  which makes better sealing. 
As seen in Figure 2-14 and 15, all types of array microvalves have 
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been tested to characterize the valve performance at various operaing 
conditions. Finally, curve (a) in Figure 2-15 can be selected as the best 
microvalve with the valve performance mimicking arachnoid granulations. 
The reason is that this valve has easy opening function under forward flow 
and better sealing effect under backward flow. Also, the flow slope (0.25 
µl/Pa·min) of this array microvalve exists within the dashed line which 
means a working zone of arachnoid villi (forward flow rate of 0.3~0.5 
ml/min at pressure difference between 500 and 1500 Pa) to be required for 
an ideal valve. 
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CHAPTER 3: AN ARRAY OF SU-8 MICRONEEDLES 
 
3.1 Review of an array of microneedles for biological 
applications 
A hypodermic syringe needle was a traditional route to inject drugs 
or extract bioliquids. This macro syringe had many shortcomings such as 
they were ineffectual, painful, and wasteful in terms of the volumes of 
bioliquids consumed. Since the introduction of Microelectromechanical 
Systems (MEMS) technology, conventional syringes could be replaced 
with microneedles for better treatment of patients. Delivering medication 
transdermally is one of the major applications of microneedles, which are 
usually made of silicon, metals or polymers. Xu et al. (2007) reported on 
an array of polymer microneedles with pyramid-shaped tips and titanium 
shield for transdermal drug or nanoparticle delivery [1]. Figure 3-1 shows 
the fabrication process. Pyramid-shaped holes are fabricated on a silicon 
wafer with a patterned oxide layer. A releasing layer was coated on this 
wafer. Then, first and second SU-8 layers were coated on the releasing 
layer and exposed using a mask with an array of clear circles to form 
microneedle arrays. AB glue or PDMS was solidified to form the needle’s 
base on the SU-8 layer. After removing the unexposed SU-8, Ti was 
sputtered to enhance biocompatibility and hardness. Roxhed et al. (2007) 
presented ultrasharp hollow microneedles for efficient transdermal drug 
delivery [2]. As shown in Figure 3-2, holes were formed for flow channels 
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Figure 3-1. Fabrication process flow: (a) The 4 in silicon wafer was 
oxidized double sides, (b) the pyramid shapes were generated on the wafer 
after KOH etching, (c) a releasing layer was coated, (d) The first SU-8 
layer was spincoated, (e) 600 μm thick SU 8 layer was spincoated and 
exposed by defined mask to form needle shaft, (f) the exposed SU-8 
polymer was heated, (g) AB glue or PDMS was solidified to form the 
needle’s base, (h) an array of microneedles was developed and separated 
from master, and (j) Ti was sputtered on it to enhance biocompatibility and 
hardness.
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Figure 3-2. Fabrication process flow of side-opened hollow 
microneedles. Microneedles were made on 600 μm thick silicon wafer 
by alternating between anisotropic Deep Reactive Ion Etching (DRIE) 
and isotripic SF6 plasma etching. 
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Figure 3-3. Process flow for fabrication of SU-8 hollow microneedle array.  
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through a 600 μm thick wafer using DRIE (Deep reactive ion etching). 
Then, a 5x5 microneedle array was made by alternating between 
anisotropic DRIE and isotropic SF6 plasma etching. The oxidation on the 
needle through the oxide etch mask was used for sharpening the needle. 
Liquid delivery through the microneedles was successively tested through 
the skin. Choi et al. (2007) reported on a three-dimensional MEMS 
microfluidic perfusion system with a SU-8 microneedle array for thick 
brain slice cultures [3]. In figure 3-3, this needle array was fabricated by a 
sequence of three processes of photolithography for the SU-8 tower, 
reactive ion etching for sharpened tips, and laser ablation for microchannel 
definition inside the needles. Bhandari et al. (2008) presented a novel 
mask-less method of fabricating high aspect ratio microneedles for blood 
sampling [4]. The fabrication process is shown in Figure 3-4. A YAG laser 
with a wavelength of 1064 nm boredholes (diameter= 80 μm and 
height=450 μm) through the silicon wafer. Rectangular columns were then 
created by making orthogonal cuts in the x and y directions using a dicing 
saw. Wet isotropic etching was performed to form sharp microneedles. 
Wang et al. (2009) presented a hollow polymer microneedle array for drug 
delivery that was fabricated by a photolithography process combined with 
replica molding technique [5]. Figure 3-5 shows the fabrication flow. A 
SU-8 layer was spincoated on a PDMS mold with a profile of pyramid tip. 
A vacuum process was performed to remove bubbles in the PDMS 
trenches. The SU-8 layer was then exposed to form the pyramid tips and 
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Figure 3-4. Process flow for fabrication of hollow microneedle array. A: 
700 μm thick silicon wafer, B: hole formation (diameter=80 μm and 
height=450 μm) using YAG laser with a wavelength of 1064 nm, C: 
rectangular columns were created by making 0.5 mm deep cuts., and D: 
isotropic etching for sharp needle. 
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Figure 3-5. Process flow for fabrication of hollow microneedle array: (a) a 
PDMS mold with profile of pyramid tip was made., (b) a 800 μm thick SU 
8 layer was spincoated and a backside vacuuming process was performed 
to remove bubbles in the PDMS trenches., (c)  a SU 8 layer with a mask 
was exposed to form pyramid tips and shafts., (d) a SU 8 layer was 
exposed to form the microneedle base., (e) the PDMS mold was removed., 
and (f) unexposed SU 8 was removed. 
105 
 
shafts. The second exposure was applied to the SU-8 layer to form the 
needle base. Next, the PDMS mold was removed and unexposed SU-8 
was developed away. Choi et al. (2010) demonstrated a 
polymethylmemethacrylate (PMMA) microneedle array with electrica 
functionality for electroporating skin’s epidermal cells to increase their 
transfection by DNA vaccines [6]. Techniques used for the needle 
fabrication are PDMS micromolding, metal deposition, laser ablation for 
patterning, and electrodeposition. The first SU-8 was spincoated and 
exposed for the needle base, and the second SU-8 layer was spincoated 
and exposed to form the tapered geometry. RIE etching was applied to 
form the sharp needle. PDMS was then cast onto the SU-8 needle array to 
form an inverse PDMS mold and a replica PMMA microneedle array was 
formed.  The Ti/Cu was sputtered on the PMMA microneedle array as a 
seed layer for electrodeposition of Ni, and the laser ablation of a metal 
layer was done to achieve electrical isolation. The next step was 
electrodeposition of Ni to enhance mechanical strength. This study 
demonstrated the mechanical and electrical functionalities of the first 
MEMS-fabricated microneedle array for electroporation designed for 
DNA vaccine delivery. 
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3.2 Design of an array of microneedles and simulation for the size 
decision of small channel inside the microneedle 
 
3.2.1. Design criteria for microneedle 
1. It must be an array type that can be assembled with a dome-petal 
microvalve array. 
2. It mest be sharp and rigid to be able to pierce dura mater. 
3. Needle height needs to be around 500 μm because the thickness 
of dura mater is about 300 μm). 
4. Hollow channel for CSF conduit: 
a. The hollow channel needs to be off center to maintain the 
sharpness of the microneedle. 
b. The channel diameter needs to be less than 50 μm to be able to 
pass through dura mater but not too small because the pressure 
drop across the channel should be minimized for proper valve 
performance. 
5. The needle should be small and biocompatible (preferably 
polymer). 
 
 
 
 
 
 
107 
 
3.2.2. Design of an array of microneedles 
Figure 3-6 shows the design of a 10x10 SU-8 microneedle array. 
The microneedles were designed to have a 500 μm-long conical shaped 
body with a sharp tip on a square base and a microchannel inside each 
microneedle to deliver CSF to the sagittal sinus. This long conical-shaped 
needle with a sharp tip is expected to puncture human dura mater with a 
thickness of 300 μm. In order to prevent the needles from being blocked 
by platelet adhesion and blood clotting, this microneedle array was 
designed as 10x 10 arrays on a base with an area of 5x5 mm2 and a 
thickness of 200 μm. The height and bottom diameter of the conical–
shaped body are 500 and 120 μm, respectively, and the distance between 
two adjacent cone centers is 400 μm. The microfluidic channels inside the 
microneedles consist of a small channel (H=300~350 μm) inside the 
needle and large channel (D=250 μm & H=150 μm) inside the base. Later, 
a 10x10 array of large holes inside the base will be aligned and bonded 
with a 10x10 array of microvalves for the MAG. In order to determine the 
diameter of the small channel, pressure drop through the channel will be 
calculated and visualized using 3D Comsol simulations. The strength and 
sharpness of the microneedles should be investigated through puncture 
testing with dura mater. The needle will be designed in order to achieve 
the optimal balance of strength and sharpness.  
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Figure 3-6. Schematic and dimensions of 10x10 conical shaped microneedle 
arrays. 
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3.2.3. Simulation for the size decision of small channel inside the 
microneedle to minimize pressure drop through the channel 
The MAG can drain CSF from the subarachnoid space (SAS) to 
the superior sagittal sinus (SSS) after implantation. A pressure drop 
through the channels inside microneedles should not affect the valve 
performance as shown in Figure 2-14 and 15. In order to minimize the 
pressure drop through the channel, 3-D numerical simulation using the 
Comsol program can be applied for calculating and visualizing the 
pressure drop through the channel.  
The geometry for this simulation was drawn based on the model 
for the microvalve simulation as shown in Figure 3-7. A small channel 
inside the needle was added in the geometry. A simulation procedure is 
very similar to the previous simulation for the microvalve. Three 
multiphysics modules of Solid Stress- Strain, Moving Mesh, and 
Incompressible Navier-Stokes were coupled in the simulation. Material 
properties and equations used in this simulation are shown in Chapter 2.2. 
All boundary conditions (BCs) necessary to determine a solution are the 
following: 1 is an inlet with an applied pressure, 2~11 are walls with a no 
slip condition, 12 is an outlet with zero pressure, and the BC of a valve in 
this geometry is the same as the BC used in the microvalve simulation. In 
the mesh generation, the predefined mesh size was set to normal. 
Maximum element sizes for this geometry were set to 5e-6 and 1e-4 m. 
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Figure 3-7. 3-D simulated geometry, dimensions and boundary conditions; 
1=inlet (BC=applied pressure), 2-11=wall (BC=no slip), 12=outlet 
(BC=zero pressure), and valve (BC=same as previous valve simulation) 
500 µm 
500 µm
250 µm 
150 µm 
300 µm
Dc (Channel diameter)
Outlet
Inlet
1
2 
3
4
5
6 
7
8
9
10
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The GMRES (Generalized Minimum Residual) solver with Incomplete 
LU was used as a parametric segregated solver. 
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3.2.4. Results and discussion 
Figure 3-8 shows the 3-D simulation calculating the pressure drop 
through the channels at 1500 Pa to predict the pressure drop through 
microvalve and microfluidic channel inside the microneedle. Figure 3-9(a) 
is the result for pressure drop through channel with a diameter of 30 μm. 
Pressure drop through this channel at 1500 Pa is 600 Pa. This pressure 
drop affects the valve performance seriously. However, Figure 3-9(b) 
shows that the pressure drop through small channel with a diameter of 40 
μm at 1500 Pa is less than 100 Pa which is acceptable. From above results, 
the channel diameter should be at least 40 μm. At the same time, current 
needle design limits the channel diameter to less than 50 μm. There are 
two reasons to limit the small channel diameter inside the needle. One is 
the channel location; the center of the channel should be located outside of 
the center of the microneedle to keep a sharp tip. The other is the 
limitation of the channel length. The height of the outlet should be over 
300 μm from the bottom (diameter 120 μm) of the cone shape to puncture 
human dura mater with a thickness of 300 μm. These analysis results came 
to the conclusion that the channel diameter should be designed as 40 μm. 
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Figure 3-8. 3-D simulation results at 1500 Pa for optimization of channel 
size inside microneedle to predict the pressure drop through microvalve and 
channel inside microneedle: (a) Dc=30 μm and (b) Dc = 40 μm. 
(a) 
(b) 
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Channel diameter (Dc, μm) 30 40 
Pressure drop (Pa) 
from Analytical solution 
622 105 
Pressure drop (Pa) 
from Simulation 
600 97 
Average velocity (m/s) 0.05 0.015 
Channel length (μm) 350 350 
Water density (Kg/m3) 1000 1000 
Dynamic viscosity (Pa·s) 0.001 0.001 
 
 
 
 
 
 
 
 
Table 3-1. Pressure drop through small channel at 1500 Pa from 
numerical simulation and analytical solution. 
∆P ൌ ଼ μ L ୳ഥ୰మ         (For analytical solution) 
 (uത= average velocity, L= channel length, r= channel radius, μ= dynamic 
viscosity, and ΔP=Pressure drop) 
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3.3 Fabrication of an array of micrneedles 
 
3.3.1 Fabrication process 
In order to fabricate a 10x10 array of microneedles, four main 
fabrication processes are required as follows; microfabrication for tapered 
geometry, RIE (Reactive Ion Etching) for a sharpened microneedle, 
Excimer laser machining for the microfluidic channel inside the 
microneedle, and Metal (Al or Ti) & Parylene deposition on the 
microneedle forstrength enhancement.  
Figure 3-9 shows the fabrication process flow for the tapered SU-8 
microstructure. First, a Cr layer on the 4x4 in glass plate is patterned. A 
dextrin solution (dextrin: DI water=1 g: 10 g) is then spin-coated on the Cr 
plate at 2000 rpm: 20s: 1000rps and baked at 120C for 2 min. This 
dextrin layer is used for easy release of the array of microneedles from the 
glass plate. To form the base, SU-8 2035 is spin-coated at 500rpm: 10s: 
300rps/ 500rpm: 30s: 300rps for 200 μm and baked at 65C for 10 min 
and 95C for 50min. It is exposed for 17.7 sec with a UV intensity of 21.2 
mW/cm2 and then baked at 65C for 5 min and 95C for 30 min. To form 
a tapered microstructure, SU-8 2150 is spin-coated at 500rpm: 10s: 
100rps/ 1000rpm: 30s: 300rps for 550 μm and baked at 65C for 5 min 
and 125C for 4 hrs. It is exposed for 235.8 sec and then baked at 65C for 
1 min and 95C for 2 hrs. Then, it is developed with SU-8 developer and 
rinsed with IPA (Isopropyl alcohol).  The microneedles are separated from 
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Figure 3-9. Fabrication process for tapered SU-8 geometry [7].  
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Spin-coat a dextrin solution 
Spin-coat SU-8 for the base and 
bake 
Expose and bake
Spin-coat a thick SU-8 and bake 
Expose form the backside and 
bake 
Develop 
Release from the glass 
Bottom 
Top 
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the glass plate in water, melting the dextrin layer. A fabricated 10x10 
array of microneedles is shown in Figure 3-9. 
Figure 3-10 shows the fabricated 10x10 array of tapered 
microstructures with different diameters. Diameters patterned on the Cr 
plate are 50, 60, 80, and 100 μm. The bottom diameters of the tapered 
microstructures are larger than those generated on Cr plate due to the 
scattered light, but the top diameter of tapered microstructures are smaller 
than those of the Cr pattern. The height of all of the needles is 550 μm. 
The second fabrication process is RIE, which is able to sharpen a 
microneedle using a plasma system (VITA; Femto Science Inc., Korea), as 
presented in Figure 3-11. Desirable operating conditions are as follows: 
gas ratio= CHF3 (20 sccm): O2 (180 sccm), pressure= 900~1500 mTorr, 
and power= RF 100 W. The power is kept constant to maintain a smooth 
surface. The optimized etch times for Figure 3-11(a), (b), (c), and (d) are 6 
min, 6 min 15sec, 8 min 10 sec, and 9 min 20 sec. At longer etch times 
beyond these, the needle height decreases significantly. 
As shown in Figure 3-10, the next process is KrF excimer laser 
machining (RAPID X250; Resonetics Co. Ltd, Nashua, NH) to make a 
microfluidic channel inside the microneedle. The excimer laser ablation is 
done in two steps to form a big channel inside the base and a small 
channel inside the cone-shaped body. First a 250 μm diameter laser beam 
is used to generate big channels from the backside and then, a 20 μm 
diameter laser beam is used to machine small channels, which are off-
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center and parallel to the cone shape. The reason to machine from the 
backside is that it is easy to align the microneedle with a laser beam and 
much less debris is produced at the needle outlet.  
The final process is the metal deposition on the SU-8 microneedle 
surface using the DC sputter system (T-M Vacuum Product, Inc., Riverton, 
NJ, USA) in Figure 3-10. The preferred metal is either Ni or Ti due to 
theirbiocompatibility and high strength. 1 μm thick Ti is deposited under 
the following conditions: Argon: 40 sccm and 30 mTorr, Power: DC 50W, 
Target temperature: room temperature, cycle: 5 min deposition & 5 min 
cooling, and total run time: 1hr 30 min. And then, 1 μm thick Parylene C 
was coated on the microneedle with a metal shield to reduce blood clots 
on the microneedle surface and to bond together using the diluted PDMS. 
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Figure 3-10. RIE, Excimer laser machining, and Metal & Parylene coating 
processes. 
Tapered microstructure 
Reactive Ion Etching 
KrF excimer laser machining 
for big channels 
KrF excimer laser machining 
for small channels 
Metal sputtering on the microneedle 
surface 
Parylene coating on the microneedle 
with a metal shield 
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3.3.2 Results and discussion 
Figure 3-11 shows the tapered SU-8 microstructures. They are 
different in appearance in terms of the Cr patterned masks, which were 
designed to have circular geometries with diameters of 50, 60, 80, and 100 
µm at a constant spacing of 400 µm. Microstructures with diameters of 
less than 50 µm collapsed due to very high aspect ratio. The heights of all 
tapered microstructures are 550 µm. The bottom diameters of the tapered 
microstructures are larger than the Cr patterned diameters, and the top 
diameters are smaller. The tapered microstructures with high aspect ratio 
like these were created by a non-uniform UV dose between top and 
bottom of the SU-8 resist as shown Figure 3-9. This non-uniform UV dose 
means that the bottom layer is overexposed and the top layer is relatively 
underexposed. The sidewall of the tapered microstructures is fairly smooth, 
and the tapered angle of the microstructures ranges between 2.9 and 3.9.  
Figure 3-12 shows sharp microneedles after the RIE process. An 
isotropic reactive ion etching enables a tapered microstructure to be made 
as a very sharp microneedle with smooth surface. The etch time for each 
tapered microstructure with different diameters depends on the gas 
stabilization time in the chamber at the beginning of the RIE process for 
each single sample. When several samples were loaded for the process, the 
etch time was decreased significantly. This process can control the etch 
time to vary the needle sharpness and height. 
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Figure 3-11. Fabricated 10x10 array of tapered microstructures; (a) Cr 
patterned D 50 μm, (b) Cr patterned D 60 μm, (c) Cr patterned D 80 μm, 
and (d) Cr patterned D 100 μm.  
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Top  
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Bottom  
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Figure 3-12. 10x10 array of sharp micrneedles after the RIE process. (Full 
scale range (0-100) in the images is 0-500 μm); (a) Cr patterned D 50 μm, 
(b) Cr patterned D 60 μm, (c) Cr patterned D 80 μm, and (d) Cr patterned D 
100 μm 
(a) (b) 
(c) (d) 
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3.4 Young’s modulus measurement of pig’s dura mater 
Pig is availabe animal with intracranial contents similar to a human. 
Therefore, the fabricated MAG will be implanted in the pig’s brain and 
monitored for in-vivo testing. In order to perform this test, it is necessary 
to puncture the pig’s dura mater with microneedles for implantation.  The 
microneedles should be strong and sharp enough to puncture dura mater. 
As there is no information for pig’s dura mater, a method to estimate the 
strength of dura mater is to measure the Young’s modulus. Many methods 
exist to measure this value for isotropic materials, but it is difficult to 
measure the Young’s modulus of a thin membrane. One idea is that the 
Young’s modulus of pig’s dura mater can be calculated from a general 
characteristic equation for a flat diaphragm using the deflection measured 
by a photonic sensor, (MTI 1000 FOTONIC SENSOR, MTI Instruments 
Inc, Albany, New York, USA) which is a non-contact instrument with the 
fiber optics for transmitting and receiving. 
First, output voltages were plotted as function of target 
displacement according to different light intensities (0.5k, 1k, and 2k) to 
make fiber optic sensor response curves to target motions as shown in 
Figure 3-13.  The optical peak is a point of inflection on the performance 
curve, which means an area where the fiber optic sensor is not sensitive to 
small target displacements.  A linear range between -1 and -5 V in the 1k 
curve was selected to precisely measure the position. 
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The second step is to measure the deflection of pig’s dura mater 
within the linear range. Figure 3-14 shows the schematic of an 
experimental setup, which consists of a syringe pump, a 1 psi pressure 
sensor, a photonic sensor, and pig’s dura mater fixed along the circular 
edge of a chamber. As dura mater is a little transparent, a small piece of 
aluminum foil was put on the center of the dura mater for improving light 
reflection. The probe of the optical sensor was moved to the effective 
range. Applied water pressure by syringe pump generated some deflection 
of dura mater and this deflection caused output voltage measured by the 
photonic sensor. This voltage was converted to the deflection. Also, the 
pressure was measured by the pressure sensor to control the deflection. 
Deflection was increased with increasing pressure up to 230 Pa.  This test 
provided all of the values for the general characteristic equation for a flat 
diaphragm. 
The last step is to calculate Young’s modulus (E) using the general 
characteristic equation for a flat diaphragm. This equation can be used for 
a flat diaphragm at any deflection. Required values for this equation are as 
follows: Poisson’s ratio (µ), radius (a) and thickness (h) of dura mater, 
pressure (P), and deflection (y0). In Table 3, all values measured and 
calculated are listed. The averaged value of the Young’s modulus of pig’s 
dura mater is 32 MPa. The correlation between Young’s modulus and 
deflection of pig’s dura mater is that Young’s modulus was inversely 
increased to deflection.  
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Syringe pump 
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mater 
Light 
Water 
Aluminium 
Pressure (P) 
Voltage (V)
Distance (1k graph) 
Membrane displacement (y0) 
y0
a
Distance
Figure 3-14. An experimental setup schematic for Young’s modulus 
measurement of pig’s dura mater. 
Young’s modulus (E) 
μ (poisson’s ratio)=0.45 
a (dura radius)=0.75 cm 
h (dura thickness)=130 μm 
General characteristic equation for a flat diaphragm at any deflection 
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Table 3-2. Young’s modulus calculation of pig’s dura mater. 
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3.5        Puncture test with pig’s dura mater 
 
3.5.1 Preparation for puncture test 
Figure 3-15 shows an experimental setup for a puncture test with 
pig’s dura mater. This setup consists of microneedle holder as a moving 
part, cap system for tension application to dura mater, and 1-axis stage 
driven by a micrometer (No. 263M, The L.S. STARRETT Co., Athol, MA, 
USA). An array of microneedles was placed and fixed on the microneedle 
holder, which is taped to the center of a moving block. In order to fix an 
array of needles on the needle holder, dextrin solution was used as 
temporary adhesive. To mimic the conditions of dura mater under constant 
tension in the brain, dura mater was fixed by cap system taped on the 
center of a fixed block. The horizontal movement of the microneedle on 
the 1-axis stage was controlled by the micrometer, which has a minimum 
resolution of 10 µm. 
Sharp and tapered SU-8 microneedles without a metal shield were 
used in the puncture tests to check if the strength and sharpness of SU-8 
microneedles without a metal shield are enough to puncture dura mater. 
Initially, an array of microneedles was moved toward dura mater until 
contact was made. This contact could be checked through the window 
shown in the schematic of Figure 3-15. The puncture test was performed 
with gradual, incremental movement of an array of microneedles after 
contact. Puncturing was checked under a stereo microscope at all locations. 
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3.5.2 Results and discussion 
Two 10x10 arrays of tapered microstructures and sharp 
microneedles with a diameter of 50 µm were used to demonstrate if any of 
them is strong and sharp enough to puncture pig’s dura mater. Figure 3-16 
shows the puncture test results for tapered microstructures. This array of 
microstructures was moved up to 580 µm toward dura mater after the 
contact with dura mater. Dura mater was not punctured by this array of 
microstructures, which can be seen in the dura mater image of Figure 3-16. 
The microstructures after the puncture test were not deformed at all. This 
result proves that these microstructures need more sharpness. 
Figure 3-17 shows the puncture test result for sharp microneedles. 
A movement of this array was made up to 590 µm toward dura mater after 
the contact with dura mater. The trace of microneedles, which did not 
puncture dura mater, is shown in the dura mater image of Figure 3-17. As 
a result of the test, all of the microneedles were bent due to low strength. 
The reason for failure in the previous tests might come from the 
sharpness of the tip. In order to rectify this issue a 5-µm layer of Parylene 
was conformally coated on the surface to increase the thickness of the 
sharp tip for greater strength. Young’s modulus (2.1 GPa) of SU-8 is 
similar to that (3.1 GPa) of Parylene. Figure 3-19 shows the microneedle 
shapes before and after coating Parylene. After coating Parylene, the sharp 
tip was relatively blunted. The puncture test was repeated with this 
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microneedle, and the result was that even though the needles displayed 
greater strength, they were still not strong enough 
The aforementioned tests show that the tapered microstructures 
require more sharpness and the sharp microneedles need higher strength. 
In order to enhance the current strength of the microneedles, the only 
alternative is a metal (Ti or Ni) layer deposited on sharp microneedles 
using DC sputter, which prevents permanent deformation of SU-8 
microneedles due to thermal stress. 
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Figure 3-16. Puncture test with tapered microstructures with a 
diameter of 50 µm. All needles were not bent after the test. 
Contact with dura mater After 330 μm movement 
After 330+250 μm movement 
10x10 array of tapered microstructures before the puncture test 
Needles trace on dura mater 
10x10 array of tapered microstructures after the puncture test 
133 
 
Figure 3-17. Puncture test with sharp microneedles with a diameter of 
50 µm. All needles were bent after the test. 
Contact with dura mater 
After 140 μm movement After 140+250 μm movement 
After 140+250+200 μm movement 
10x10 array of microneedles 
before the puncture test 
No needle trace on dura mater 
10x10 array of microneedles after the puncture test 
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Figure 3-18. Puncture test with 5 µm Parylene coated sharp 
microneedles with a diameter of 50 µm. All needles were still bent 
after the test. 
After 5µm Parylene coating 
10x10 array of microneedles after the puncture test 
Before Parylene coating 
10x10 array of microneedles before the puncture test 
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3.6  Titanium coating on SU-8 needle to improve the strength 
Previous puncture test results proved that the current SU-8 needle 
is not strong enough to puncture the dura mater. A metal layer on the SU-8 
needle is needed to improve the strength. A sputtering method should be 
used to deposit Ti on the side of the needle. 
A DC sputter system (T-M Vacuum Product, Inc., Riverton, NJ, 
USA) at Rowan University has been used to deposit Ti. Initial conditions 
were Ar with 40 sccm and 10 mTorr, DC power with 150 W, room 
temperature as target temperature, and 30 min run time. These conditions 
caused the needle base to bendbecause of high thermal residual stresses 
inside the needle as shown in Figure 3-19(a). This bending created cracks 
in and delamination of the Ti layer on the needle base. In order to protect 
the base from bending, DC power was decreased to 100W. This power 
required a 1-hr run time for a 1-μm thick layer of Ti. However, the base 
was still bent a little, and minor cracks were seen on the surface as shown 
in Figure 3-19(b).  
In order to reduce the temperature during the process, power 
should be decreased and Ar pressure should be increased. Increased Ar 
pressure can increase neutral Ti particles, which can block the heat 
transfer to the samples inside the chamber. A disadvantage of this recipe is 
longer time (3 hrs) it takes dueto the cooling cycle. The conditions are as 
follows; applied DC power of 50 W. each cycle of 5 min deposition and 5 
min cooling, and Ar pressure of 30 mTorr. The total run time was 1 hr and 
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30 min. Figure 3-19(c) shows a Ti layer deposited without bending and 
cracks. Although the surface is not uniform due to high Ar pressure, Ti 
was deposited without a thermal problem. A small grain-like structure can 
be seen on the needle area. This structure may be caused by insufficient 
combination energy of atom to atom at room temperature.   
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Figure 3-19. Ti layer deposited at (a) 150 W, (b) 100 W, and (c) 50 W.  
(a) 
(b) 
(c) 
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3.7 Puncture test with a Ti coated SU-8 needle 
Based on previous puncture tests, the SU-8 needle required a metal 
layer to improve the strength. Therefore, a 1 μm thick Ti layer was coated 
on the SU-8 needle with a parylene shield that was used in the second 
puncture test. The second puncture test was the same as previous one. 
Figure 3-20 shows the results of the second puncture test. The 1100 μm 
movement of the needle toward the dura mater resulted in piercing by six 
out of 100 needles. Although a few needles were pierced, most of the 
needles after the puncture test were not bent, which proved that the needle 
is strong enough for our application. This problem was due to the elastic 
deformation of the dura mater.When the needle pushed the dura mater 
gradually, the dura mater was deformed elastically. This kind of 
deformation might disturb the piercing of all needles. 
In order to develop the puncture technique, an impact force to the 
needle was employed before starting to deform. This idea was originated 
from installing the Utah array. They used some pressure gun to implant a 
metal needle array into the brain for the purpose of sending and receiving 
neural signals.  There is no space in the brain to accommodate an 
additional device; therefore, this puncture test utilized some impact force 
generated by a finger. As shown in Figure 3-21, the result was that a third 
of a hundred needles pierced the dura matter. This puncture test still 
should be considered deeply for piercing of the dura mater.   
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(a) (b) 
(c) (d) 
Figure 3-20. Second puncture test. (a) contact with the dura mater, (b) 
after 1100 μm movement of the needle toward the dura mater, (c)  pierced 
needle, and (d) the needle after the puncture test. 
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Figure 3-21. Third puncture test. (a) 10x10 needle array before the test, (b) 
needle array pierced through the dura mater using an impact force, and (c) 
pierced needles magnified. 
(a) (b) 
(c) 
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3.8  In-vitro biocompatibility test using a 10x10 needle array 
 
3.8.1 Objective of this test 
Once the needle was designed and fabricated, it should be tested if 
it is biocompatible using blood samples prior to clinical trials. The in-vitro 
biocompatibility test serves two purposes:  
1. To examine the device performance in more physically relevant 
conditions. 
2. To predict the possibility of device blockage due to blood coagulation 
by investigating platelet adhesion characteristics. 
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3.8.2 Experiment precedure 
Commercially available human blood containing an anti-coagulant 
K2 EDTA was used in this test. Platelet adhesion is not hindered by the 
anti-coagulant. The test was performed in the incubator in which blood 
cells can be viable during the test. Two chambers were designed based on 
the real volumes of SAS (Subarachnoid space) and SSS (Superior sagittal 
sinus). Chamber 1 (1x1x5 cm3) was filled with whole blood pushed by a 
small syringe and chamber 2 (5x5x5 cm3) was filled with saline solution 
pushed by a large syringe. Since both syringes have different sizes, this 
size difference generated pressure difference (1700 Pa at 0.333 ml/min) 
between chamber1 and chamber2. This pressure could make a forward 
flow from chamber2 to chamber1. The needle was placed between two 
chambers and the needle outlets were placed in the opposite direction of 
blood flow during the test. The needle was allowed to react with blood for 
1hr. After the test, the needle was taken out of the experimental setup and 
investigated under the microscope. Then, it was rinsed with PBS 
(Phosphate buffered saline) several times. The needle was investigated 
again under the microscope. Later, more investigation will be done using 
SEM (Scanning electron microscopy) images which can provide better 
visualization of platelet adhesion.   
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Incubator 
20 cc syringe (HSW) for saline 
12 ml syringe (Monoject) for blood  
Syringe pump 
Pressure sensor 
Chamber1: Blood 
Chamber2: Saline 
Outlet 
Figure 3-22. Biocompatibility test setup in the incubator. This setup consists 
of syringe pump, pressure sensor, blood & saline chambers, and two syringes 
with different size. 
Chamber1: Blood 
Chamber2: Saline 
Sealing  
rubber 
Pressure 
sensor 
Syringe 
pump 
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3.8.3 Results and discussion 
Figure 3-23 shows the results of the biocompatibility test under a 
dynamic condition. (a) is the microscopic images of the needle right after 
the test. A lot of red blood cells reside on the needle surface.  (b) is the 
microscopic images of the needle after rinsing with PBS (Phosphate-
buffered saline) several times. Many cells were removed after rinsing. Still 
the needle has a light red color due to remaining red blood cells. (c) is the 
side view and the hole at the outlet of the needle. The objective of this test 
is to check the blockage of the holes caused by platelet adhesion. The right 
microscopic image of Figure 3-23(c) shows the outlet of the needle, which 
is not blocked by platelet adhesion based on the microscopic investigation. 
However, an inside channel could not be inspected under the microscope. 
A SEM image will be taken to see this channel in detail and calculate the 
number of platelets.  
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Figure 3-23. Biocompatibility test results. (a) right after the test, (b) after 
rinsing with PBS, and (c) Side view and hole of the needle after rinsing with 
PBS. 
(a) 
(b) 
(c) 
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK 
 
4.1 Conclusions 
The shunt systems, current main treatment of hydrocephalus, have 
over 50% failure rates due to occlusions, infection, and mechanical 
failures of shunt components. In order to address this need, we proposed 
an innovative treatment of hydrocephalus to replace deficient arachnoid 
granulation with “Microfabricated Arachnoid Granulation (MAG)”. This 
device can mimic the function (diverting CSF from Subarachnoid space to 
Superior sagittal sinus) of normal arachnoid granulation and consist of 
arrays of microvalves and microneedles.  
Dome petal design was selected as proper design of the 
microvalve. Such geometry enables the microvalve to rectify fluid flow in 
the forward and backward direction due to pressure differentials like 
normal aracnoid granulation. PDMS/Parylene composite layer was 
chosen as materials of the microvalve considering biocompatibility and 
self-sealing property of PDMS. The design parameters of the microvalve 
were optimized using 3-D numerical simulation. The microvalves were 
fabricated using three main microfabrication techniques: diffuser 
lithography for dome-shaped SU-8 mold fabrication, thin polymer film 
deposition and reflow for PDMS/Parylene membrane formation, and 
excimer laser machining for valve opening.  After parylene deposition on 
PDMS layer, lots of wrinkles only on the base of the microvalve were 
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observed. If a rigid plate is subjected to stress and attached to a soft 
elastic medium, it is very likely that this stress is relieved by wrinkling: 
The composite plate buckles into a large number of waves and the pattern 
and size of the wrinkles depend on the thickness of the materials as well 
as the thickness ratio. The pressure drop vs. flow rate characteristics of 
the fabricated microvalve was investigated through in-vitro flow tests 
using a bench-top CSF simulator. An ideal microvalve for the treatment 
of hydrocephalus needs to have a cracking pressure close to zero, a 
forward flow rate of 0.3~0.5 ml/min at pressure differences between 500 
and 1500 Pa.  The results showed that a 10x10 microvalve array with 
combined opening shape (200  μm x 60 μm) is optimal for our application.  
The microneedles were designed to have a 500 μm-long conical 
shaped body with a sharp tip on a square base and a microchannel inside 
each microneedle to deliver CSF to the sagittal sinus. This long conical-
shaped needle with a sharp tip is expected to puncture human dura mater 
with a thickness of 300 μm. In order to prevent the needles from being 
blocked by platelet adhesion and blood clotting, this microneedle array 
was designed as 10x 10 arrays on a base with an area of 5x5 mm2 and a 
thickness of 200 μm. The height and bottom diameter of the conical–
shaped body are 500 and 120 μm, respectively, and the distance between 
two adjacent cone centers is 400 μm. The microfluidic channels inside the 
microneedles consist of a small channel (H=300~350 μm) inside the 
needle and large channel (D=250 μm & H=150 μm) inside the base. The 
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microneedles were fabricated using three main techniques: diffraction 
photolithography for tapered SU-8 needle fabrication, RIE etching for 
needle sharpening, and excimer laser machining for through-hole creation. 
Puncture tests were conducted using pig’s dura mater under tension 
generated by capping system for mimicking in-vivo environment in the 
brain. As incremental insertion method caused dura mater to be deformed 
elastically, impact insertion method was adopted for better puncturing. 
The microneedles coated with a Ti layer showed promising results (16 out 
of 100 needles pierced dura and the needles were not deformed). Blood 
adhesion tests were also carried out using human blood simulating the 
CSF dynamics and no significant platelet adhesion was observed at the 
microneedles.  
The MAG proposed for better treatment of hydrocephalus has been 
designed, simulated, fabricated, and tested successfully. It demonstrated a 
great potential for the treatment of hydrocephalus. 
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4.2 Future work 
While we have been able to design, simulate, fabricate, and test the 
microvalve and the microneedle separately, we have yet to assemble the 
microneedle and the microvalve. In order to bond the microneedle with the 
microvalve together, diluted PDMS will be used as adhesive.  
More in-vitro tests such as flow test, puncture test, and 
biocompatibility test will be performed using the assembled device 
(Microfabricated arachnoid granulation). Also, this device should be 
checked if current sterilization methods cause any damage to the MAG.  
In-vitro test using pigs prior to clinical trial will also be performed 
to demonstrate the efficacy of the surgical techniques for implantation and 
to determine the short-term biocompatibility and acute toxicity related to 
the MAG. 
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